Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Kliniske og fysiologiske studier av tremorsyndromer

Background:

Researchers have some data on how the brain controls movement and why some people have tremor. But the causes of tremor are not fully known. Researchers want to study people with tremor to learn about changes in the brain and possible causes of tremor.

Objective:

To better understand how the brain controls movement, learn more about tremor, and train movement disorder specialists.

Eligibility:

People ages 18 and older with a diagnosed tremor syndrome

Healthy volunteers ages 18 and older

Design:

Participants will be screened with:

  • Medical history
  • Physical exam
  • Urine tests
  • Clinical rating scales
  • Health questions
  • They may have electromyography (EMG) or accelerometry. Sensors or electrodes taped to the skin measure movement.

Participation lasts up to 1 year.

Some participants will have a visit to examine their tremor more. They may have rating scales, EMG, and drawing and writing tests.

Participants will be in 1 or more substudies. These will require up to 7 visits. Visits could include the following:

  • EMG with accelerometry
  • Small electrodes taped on the body give small electric shocks that stimulate nerves.
  • MRI: Participants lie on a table that slides into a cylinder that takes pictures of the body while they do simple tasks.
  • Small electrodes on the scalp record brain waves.
  • A cone with detectors on the head measures brain activity while participants do tasks.
  • A wire coil held on the scalp gives an electrical current that affects brain activity.
  • Tests for thinking, memory, smell, hearing, or vision
  • Electrodes on the head give a weak electrical current that affects brain activity.
  • Photographs or videos of movement

Participant data may be shared with other researchers.

Studieoversikt

Detaljert beskrivelse

Objectives

The purpose of this protocol is to study the phenotypic spectrum and the pathophysiology of tremor syndromes by performing small behavioral, electrophysiological and neuroimaging sub-studies. The protocol includes techniques with minimal risk (standard clinical evaluation, MRI, EEG, peripheral nerve stimulation, single and paired pulse TMS) and certain sub-studies may involve healthy volunteers. This protocol aims to study neurophysiological and behavioral outcomes in defined groups of patients with tremor syndromes, to inform future hypothesis-driven and confirmatory studies, which will be developed and submitted as separate protocols. For this purpose, we aim to conduct 1) pilot sub-studies, 2) individual patient investigations, 3) technical development studies.

Study population

We intend to enroll up to 300 patients with essential tremor and other isolated action tremor syndromes, as well as 150 healthy volunteers.

Design

This is a non-hypothesis driven study involving standardized phenotyping After patients and healthy volunteers complete a screening visit, patients will undergo a standardized phenotyping visit including clinical rating scales as well as electrophysiological tremorworkup. Patient and healthy controls may then be enrolled in sub-studies, and if a substudy leads to results of interest, a separate protocol will be submitted with a priori hypotheses, specific study design and power analysis adapted from the pilot or exploratory sub-studies performed in the present protocol.

Outcome measures

Outcome measures applied in this protocol involve methods for tremor phenotyping such as clinical rating scales and questionnaires, electrophysiological tremor studies, videotaped exam, as well as digitizing based tasks. During the sub-studies focused on the neurophysiological characterization of tremor syndromes, the following outcome measures will be applied: EMG: we will analyze tremor signals using spectral analyses, coherence analyses, and in combination with accelerometry, EEG, MEG, and TMS to explore tremor-networks. MRI: we will analyze measures such as the amplitude of the BOLD signal (fMRI); tractography between seed and target regions of interest (using DTI); morphometry of brain regions (using VBM); and different neurotransmitter levels in brain regions of interest (using MRS). EEG and MEG: we will quantify measures such as corticomuscular coherence, event- or task-related potentials, synchronization/desynchronization, and coherence between sensors or sources located close to the brain areas of interest. TMS: we will analyze measures such as MEP amplitude and central conduction time, as well as measures of cortical excitability and inhibition paradigms. Behavioral measures: we will quantify measures of voluntary movement involving tremor, reaction times to initiate movements, EMG patterns, movement kinematics (position, velocity, acceleration, curvature), eye movement. Actigraphy: We will quantify continuous recordings of motion sensors involving multiaxial accelerometers and gyroscopes. Furthermore, we may measure autonomic data during the course of experiments (such as blood pressure, skin co ductance, and respiratory rate) which would correlate to the outcome measures.

Studietype

Observasjonsmessig

Registrering (Faktiske)

85

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Maryland
      • Bethesda, Maryland, Forente stater, 20892
        • National Institutes of Health Clinical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Experimental subjects will include healthy volunteer subjects and patients with tremor syndromes including, but not limited to ET, PD-tremor, and dystonic tremor. The diagnosis will be made by a movement disorders neurologist at the NINDS movement disorders clinics. Healthy volunteers will be recruited for the following purposes: (1) to optimize data acquisition and analysis techniques; and (2) to serve as negative controls for clinical, imaging, and biological variables measured in the patient cohorts. Without data obtained from healthy volunteers, there is no way to determine whether subtle findings in tremor (e.g., physiological tremor) are truly abnormal. The inclusion of healthy volunteers therefore allows to correctly threshold and quantify observed abnormalities. Healthy volunteers may also include non-affected family members of patients with tremor

Beskrivelse

  • INCLUSION CRITERIA FOR TREMOR PATIENTS:

  • Patients diagnosed with a tremor syndrome, including, but not limited to

    • Essential tremor (per definition of the Tremor Research Group)
    • Parkinson disease (per UK Brain Bank criteria)
    • Focal tremor such as isolated head tremor, voice tremor
    • Task-specific tremor such as primary writing tremor
    • Orthostatic tremor
    • Patients with other tremor syndromes such as dystonic tremor, intention tremor, etc.
  • Age 18 or older

  • Able to give informed consent

  • Agree to not drink caffeine or alcohol for 12 hours before phenotyping and selected sub-study visits because both agents can modify brain activity and may confound outcome measures.

INCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  • Age 18 or older.
  • Able to give informed consent.
  • Agree to not consume caffeine or alcohol for 12 hours before selected sub-study visits because both agents may modify the activity of the brain during the study.

EXCLUSION CRITERIA FOR TREMOR PATIENTS:

  • Problematic alcohol use, as defined by a score of 8 or higher on the WHO Alcohol Use Disorders Identification Test (AUDIT).
  • History of a brain tumor, a stroke, traumatic brain injury, epilepsy or a history of seizures.
  • History of psychotic disorder, Bipolar Disorder or a current depressive episode.
  • History or clinical evidence of another neurologic disorder than a tremor syndrome as defined above, which may interfere with the ability to comply with protocol requirements or interpret the obtained results.

EXCLUSION CRITERIA FOR HEALTHY VOLUNTEERS:

  • Have abnormal findings of clinical significance on the neurological examination that may affect the scientific integrity of the study
  • Problematic alcohol use, as defined by a score of 8 or higher on the WHO Alcohol Use Disorders Identification Test (AUDIT)
  • History of a brain tumor, a stroke, traumatic brain injury, epilepsy or a history of seizures.
  • History of psychotic disorder, Bipolar Disorder or a current depressive episode.

ADDITIONAL EXCLUSION CRITERIA FOR MOVEMENT DISORDER PATIENTS AND HEALTHY VOLUNTEERS SPECIFICALLY FOR MRI:

We will follow the NMR Center guidelines for MR safety.

Some of the exclusions are:

  • Have non-MRI compatible metal in the body, such as a cardiac pacemaker, brain stimulator, shrapnel, surgical metal, clips in the brain or on blood vessels, cochlear implants, artificial heart valves or ferromagnetic fragments in the eye or oral cavity as these make having an MRI unsafe.
  • Unable to lie flat on the back for the expected length of the experiment.
  • Have uncontrolled movements of the head.
  • Have an abnormality on the brain imaging or neurologic examination not related to the diagnosis.
  • Uncomfortable being in a small space for the expected length of the experiment.
  • Non-removable body piercing or tattoo posing MRI risk
  • Pregnancy.

ADDITIONAL EXCLUSION CRITERIA FOR TREMOR PATIENTS AND HEALTHY VOLUNTEERS FOR TMS AND MRI:

  • Ferromagnetic metal in the cranial cavity or eye, e.g. aneurysm clip or ocular foreign body.
  • Implanted electronic device including deep brain stimulation systems.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Healthy Volunteers

adult healthy volunteers

tremor patients

adult patients with tremor

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
methods for tremor phenotyping
Tidsramme: throughout protocol

clinical rating scales and questionnaires, electrophysiological tremor studies, videotaped exam, as well as digitizing based tasks. EMG, EEG, MEG, TMS, MRI. Behavioral measures such as reaction times to initiate movements, EMG patterns, movement kinematics, eye movement.

throughout protocol

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Debra J Ehrlich, M.D., National Institute of Neurological Disorders and Stroke (NINDS)

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

5. mai 2017

Primær fullføring (Faktiske)

23. mars 2022

Studiet fullført (Faktiske)

23. mars 2022

Datoer for studieregistrering

Først innsendt

18. januar 2017

Først innsendt som oppfylte QC-kriteriene

20. januar 2017

Først lagt ut (Antatt)

23. januar 2017

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

17. september 2026

Sist bekreftet

16. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

We will share all collected deidentified IPD at the request of others after publication. Data will not be sent until the applicable approvals and data sharing agreement has been obtained.

IPD-delingstidsramme

Starting 6 months after publication.

Tilgangskriterier for IPD-deling

Requests will be considered on a case-by-case basis and we will try to uphold the NIH data-sharing directive. At the same time we may need IRB approval and/or data sharing agreements to be in place before we send data to others.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere